Sama Therapeutics
Russell Hanson serves as the Chief Innovation Officer at Sama Therapeutics, focusing on precision neuropsychiatry through AI and machine learning. In addition, Russell functions as an AI & Data Science Advisor at Superduper and provides advisory services at Equideum Health and Ligandal. Russell has held key positions as Chief Scientific Officer and Co-Founder at Aptavid, where significant advancements in AI and biomarker development were made, particularly in rapid COVID-19 testing. Previously, Russell was Chief Scientist at Augustus Intelligence, leading AI efforts for Fortune 500 companies, and served as Chief Scientific Officer at ConsenSys, specializing in AI for cryptocurrency. Russell's academic background includes various educational institutions and a role as Assistant Professor at the Icahn School of Medicine at Mount Sinai, concentrating on genomics and multiscale biology.
This person is not in any teams
Sama Therapeutics
1 followers
Sama Therapeutics is a precision neuropsychiatry AI/ML platform that synthesizes and validates predictive biomarkers grounded in neural, physiological, multi-omics, natural language, and behavioral phenotypes. The company's agile SaaS platform, iMAGiNE™, analyzes the transdiagnostic efficacy of pharmaceutical and neurostimulation modalities through precision clinical trials, causal inference, preclinical translation, and generative AI trained on proprietary and open-science datasets. With an extraordinarily interdisciplinary team, Sama Therapeutics is advancing "software as medical device" for a range of indications, including cognitive, affective, interoceptive, and substance use disorders. We invite partners to join our mission unlocking brain health through integrative neurotechnology and proven “transprognostic” algorithms: https://brainclinics.com/tdbrain-challenge/ Please reach out to contact@sama.ac for more information and a live demo.